Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASCO 2024

31 May - 4 Jun 2024

McCormick Place, Chicago, United States of America

ASCO 2024: Innovative combination therapy shows promise for bladder cancer patients unresponsive to standard treatment

ASCO 2024: Innovative combination therapy shows promise for bladder cancer patients unresponsive to standard...

ASCO 2024: Sarcoma clinical trial reduces risk of relapse by 43%

ASCO 2024: Sarcoma clinical trial reduces risk of relapse by 43%

ASCO 2024: Promising results from the first clinical trial of an innovative next-generation antibody in patients with advanced solid tumours, especially in melanoma

ASCO 2024: Promising results from the first clinical trial of an innovative next-generation antibody in patients...

ASCO 2024: Spanish-language content for lung cancer patients helps break down barriers to care

ASCO 2024: Spanish-language content for lung cancer patients helps break down barriers to care

ASCO 2024: Telehealth can significantly reduce greenhouse gas emissions associated with cancer care, study finds

ASCO 2024: Telehealth can significantly reduce greenhouse gas emissions associated with cancer care, study finds

ASCO 2024: Immunotherapy significantly increases the number of patients free from bowel cancer

ASCO 2024: Immunotherapy significantly increases the number of patients free from bowel cancer

ASCO 2024: Trial reveals benefits of ‘stepped’ palliative care for patients with advanced lung cancer

ASCO 2024: Trial reveals benefits of ‘stepped’ palliative care for patients with advanced lung cancer

ASCO 2024: Research group completes first trial of Black patients with early-stage breast cancer

ASCO 2024: Research group completes first trial of Black patients with early-stage breast cancer

ASCO 2024: New ‘Armoured’ CAR produces significant responses in patients whose cancers don't respond to current CAR T cell therapies

ASCO 2024: New ‘Armoured’ CAR produces significant responses in patients whose cancers don't respond to current...

ASCO 2024: Experimental therapy shows promise in pancreatic cancer clinical trial

ASCO 2024: Experimental therapy shows promise in pancreatic cancer clinical trial

ASCO 2024: Drug targeting protein involved in control of immune response produces encouraging results in glioblastoma

ASCO 2024: Drug targeting protein involved in control of immune response produces encouraging results in...

ASCO 2024: CAR T-cell therapy shows promise in patients with central nervous system lymphoma

ASCO 2024: CAR T-cell therapy shows promise in patients with central nervous system lymphoma

ASCO 2024: Antibody-drug conjugate plus checkpoint inhibitor shows a trend toward improved progression-free survival in PD-L1-positive hormone receptor-positive, HER2-negative breast cancer

ASCO 2024: Antibody-drug conjugate plus checkpoint inhibitor shows a trend toward improved progression-free...

ASCO 2024: Telehealth as effective as in-person care for early palliative treatment in patients with advanced lung cancer

ASCO 2024: Telehealth as effective as in-person care for early palliative treatment in patients with advanced lung...

ASCO 2024: Trastuzumab deruxtecan significantly improves progression-free survival In breast cancer patients previously treated with endocrine therapy

ASCO 2024: Trastuzumab deruxtecan significantly improves progression-free survival In breast cancer patients...

ASCO 2024: Chemotherapy before and after surgery may be new standard treatment for some patients with oesophageal cancer

ASCO 2024: Chemotherapy before and after surgery may be new standard treatment for some patients with oesophageal...

ASCO 2024: Durvalumab following chemoradiotherapy improved survival in patients with limited-stage small-cell lung cancer

ASCO 2024: Durvalumab following chemoradiotherapy improved survival in patients with limited-stage small-cell lung...

ASCO 2024: Osimertinib poised to change standard of care treatment for patients with locally advanced EGFR-mutated NSCLC

ASCO 2024: Osimertinib poised to change standard of care treatment for patients with locally advanced EGFR-mutated...

ASCO 2024: Dual immunotherapy treatment before surgery, rather than after, improves outcomes in melanoma patients

ASCO 2024: Dual immunotherapy treatment before surgery, rather than after, improves outcomes in melanoma patients

ASCO 2024: Lymphadenectomy may not be needed for patients with advanced ovarian cancer

ASCO 2024: Lymphadenectomy may not be needed for patients with advanced ovarian cancer

ASCO 2024: Adding belantamab mafodotin to multiple myeloma treatment combinations slows disease progression or death

ASCO 2024: Adding belantamab mafodotin to multiple myeloma treatment combinations slows disease progression or...

ASCO 2024: Shorter durations of venetoclax yields similar response rates in AML

ASCO 2024: Shorter durations of venetoclax yields similar response rates in AML

$ASCO 2024: Novel CAR T cell therapy obe-cel yields strong remission rates in adults with relapsed or refractory B-ALL$

ASCO 2024: Novel CAR T cell therapy obe-cel yields strong remission rates in adults with relapsed or refractory B...

ASCO 2024: Novel therapy combination more effective at treating Hodgkin lymphoma than established treatment

ASCO 2024: Novel therapy combination more effective at treating Hodgkin lymphoma than established treatment

ASCO 2024: Prostate cancer spit test better for men with high genetic risk than standard blood test

ASCO 2024: Prostate cancer spit test better for men with high genetic risk than standard blood test

ASCO 2024: New study details longest progression-free survival ever reported in advanced NSCLC

ASCO 2024: New study details longest progression-free survival ever reported in advanced NSCLC

ASCO 2024: Asciminib may be safer, more effective treatment option for patients with newly diagnosed chronic myeloid leukaemia

ASCO 2024: Asciminib may be safer, more effective treatment option for patients with newly diagnosed chronic...

ASCO 2024: Oestrogen-only hormone therapy may increase cancer risk while oestrogen-progestin combination may lower risk

ASCO 2024: Oestrogen-only hormone therapy may increase cancer risk while oestrogen-progestin combination may lower...

ASCO 2024: Artificial intelligence-based patient navigator may help improve disparities in colon cancer screening

ASCO 2024: Artificial intelligence-based patient navigator may help improve disparities in colon cancer screening

ASCO 2024: Risk reduction from HPV vaccination goes beyond cervical cancer

ASCO 2024: Risk reduction from HPV vaccination goes beyond cervical cancer

ASCO 2024: Most younger breast cancer patients can conceive, give birth after treatment

ASCO 2024: Most younger breast cancer patients can conceive, give birth after treatment

ASCO 2024: Combination therapy significantly improves outcomes for patients with metastatic colorectal cancer

ASCO 2024: Combination therapy significantly improves outcomes for patients with metastatic colorectal cancer

More from ecancer